February 27, 2023Annals of Oncology126 citationsOpen Access

Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer

SCS. Chowdhury ABAnders Bjartell NANeeraj Agarwal

Key Points

Key points are not available for this paper at this time.

Abstract

Apalutamide plus ADT demonstrated a robust (rapid, deep, and durable) PSA decline that was associated with improved clinical outcomes, including long-term survival.

KI fragen

Bookmark

View Full Paper